The conventional wisdom is that 510(k) is faster and cheaper than De Novo. Submit a 510(k), wait 90 days, you're cleared. De Novo takes 150 days and costs 4x more in user fees. So naturally, founders default to 510(k)—even when their device is genuinely novel and has no legitimate predicate. The result: FDA issues an information request or denial, the company is forced into De Novo anyway, and they've wasted 6+ months and $500K+ on a failed 510(k) submission. The strategic advantage of De Novo—creating a new device classification and moat against competition—is lost.
This article breaks down when De Novo is actually the right choice, how to evaluate the cost-benefit decision, and why the "cheaper path" is often the most expensive.
The Math: 510(k) vs De Novo Head-to-Head
User Fees: De Novo user fee is $135K. That's 4.4x higher than 510(k). But the timeline comparison is more nuanced: FDA's 90-day and 150-day clock starts when they "accept" the application. If they determine your 510(k) has insufficient information or an inappropriate predicate, they issue an information request, which adds 30-90 days (or more, if you need to resubmit).
Regulatory Consulting Costs: 510(k) submissions: $50-150K in consulting fees. De Novo submissions: $200-400K in consulting fees (more rigorous clinical/technical documentation required).
The Forced Conversion Scenario: You submit a weak 510(k), FDA rejects it with an IR (information request) or denial, you convert to De Novo. You've now spent $31K + consulting fees on a failed 510(k), plus $135K + consulting fees on De Novo. Total: $166K+ in user fees alone, plus $300-400K in consulting. Total timeline: 18-24 months (vs. 5-6 months if you'd done De Novo upfront).
When 510(k) Makes Sense
The 510(k) pathway is appropriate when:
- A legitimate predicate device exists (not an approximation, but a truly similar device legally marketed by FDA in the same general category)
- Your device is substantially equivalent in intended use and technological characteristics (this is the actual regulatory standard—no shortcuts)
- You have confidence FDA will agree with your predicate selection (based on FDA pre-submission guidance or published guidance documents)
- Clinical data requirements are minimal (because substantial equivalence means equivalence, not superiority)
If any of these conditions are questionable, you're at risk of 510(k) rejection and forced conversion to De Novo.
When De Novo is the Right Move
De Novo is appropriate (and strategically valuable) when:
- Your device represents a novel technology with no clear predicate (e.g., first-in-class AI diagnostic, novel implant material, new modality)
- You have strong clinical data demonstrating safety and effectiveness even without predicate comparison
- You want to establish yourself as the predicate for future competitors (De Novo creates a new device classification, which means future similar devices will be compared to you, not to some legacy predicate)
- You're willing to accept 150-day timeline if it means regulatory clarity and competitive advantage
De Novo also has a hidden advantage: FDA explicitly states in the decision that your device creates a new classification. This creates regulatory certainty and potentially makes your device an attractive acquisition target (strategic buyers want devices with clear regulatory positioning, not devices with weak predicates that might face future challenges).
De Novo Creates Strategic Moat
When FDA issues a De Novo decision, it establishes a new classification specific to your device's characteristics. Future competitors building similar devices will be classified under the same pathway—and their applications will be judged against your device as the predicate. This is a competitive advantage that 510(k) clearance doesn't provide.
Real-World Case Studies
Case 1: The Weak 510(k) Failure
An early-stage company developed a novel transdermal patch technology using a never-before-approved penetration enhancer. They selected a 510(k) pathway with a legacy transdermal patch from the 1990s as predicate. FDA's position: "Your penetration enhancer technology is fundamentally different. The old predicate patch doesn't help prove substantial equivalence of your new technology."
Result: 510(k) denial. Company forced into De Novo. Total timeline: original 510(k) (90 days) + resubmission period (60 days) + De Novo submission (150 days) = 300 days. They could have done De Novo upfront in 150 days. Cost penalty: 6+ months of additional development/consulting, plus user fee duplication ($31K wasted on 510(k)).
Case 2: The Strategic De Novo Win
A medical device company developed the first AI-powered real-time pathology analysis system. No predicate existed (no prior AI pathology system had ever received FDA clearance). They chose De Novo upfront, conducted robust clinical validation, submitted with comprehensive technical documentation.
Result: De Novo approval in 150 days. Established new classification: "AI-enabled pathology analysis systems." Now, all future pathology AI competitors will reference this company's device as the predicate. The company achieved regulatory certainty, established first-mover classification advantage, and positioned itself as the "predicate setter" in a new category.
Strategic value: This positioning made the company an attractive acquisition target. Strategic buyers seeking to enter the AI pathology space wanted a device with clear regulatory precedent, not the regulatory risk of building something without predicate support.
Decision Framework: When to Choose De Novo
Ask yourself:
- Can I name a single predicate device that my device is substantially equivalent to? If you're struggling to answer this, you need De Novo.
- Am I confident FDA will agree with my predicate selection based on their guidance documents? If not, 510(k) is risky.
- Do I have clinical data demonstrating my device is safe and effective? If yes, De Novo is viable.
- Is competitive positioning important to my exit strategy? If you want acquirers to view your device as the "predicate setter" in a new category, De Novo creates that advantage.
- Can I afford 150 days vs. 90 days? If timeline is critical, 510(k) might be worth the risk (but only if predicate is strong).
If you answer "no" to #1 or #2, De Novo is likely the right choice, even if it costs more upfront.
The Hybrid Approach: Pre-Submission Strategy
The most sophisticated companies use FDA's free pre-submission program to answer the De Novo vs 510(k) question before committing resources. They present their device, proposed predicate (if 510(k)), clinical data plan, and substantial equivalence arguments. FDA responds: "Your pathway is appropriate" or "We recommend De Novo instead." This 3-month pre-submission conversation costs nothing and prevents $500K+ mistakes.
The Long-Term Portfolio Advantage
From an investor perspective, a De Novo-cleared device often commands a valuation premium over a 510(k)-cleared device in the same category. Why? Because De Novo signals:
- Clear regulatory precedent (lower risk of future regulatory challenges)
- Substantive clinical validation (not just substantial equivalence claims)
- First-mover classification advantage (competitors will reference your device as predicate)
- Stronger acquisition appeal (strategic buyers view De Novo devices as anchors in new categories)
This premium can exceed the additional cost of De Novo, making it the economically superior choice even when 510(k) appears "cheaper."
Red Flag: Forced 510(k) Strategy
Company claims they must use 510(k) because it's "faster and cheaper," but their device is truly novel with no clear predicate. This is a forced pathway that will likely fail, creating downstream regulatory and timeline risk. De Novo, despite higher upfront cost, is strategically superior.
The Bottom Line
The 510(k) pathway is faster only if your predicate is solid and FDA agrees with your substantial equivalence arguments. If you force a 510(k) with a weak or inappropriate predicate, you'll face rejection, forced conversion to De Novo, and a 12-18 month timeline penalty—worse than choosing De Novo upfront. Companies with genuinely novel devices should seriously consider De Novo: it provides regulatory clarity, competitive advantage, and often better strategic positioning for exit and acquisition. The "cheaper path" is often the most expensive when you account for failed submissions and timeline slippage.
"The cost of a failed 510(k) and forced De Novo conversion is 10x the cost of choosing De Novo upfront."
References
- FDA. "De Novo Classification Requests: Process and Guidance." fda.gov
- FDA. "510(k) Submission Strategy and Pre-submission Meetings." fda.gov
- FDA. "Device Classification and Regulatory Pathways." fda.gov
- FDA CDRH. "510(k) Substantial Equivalence Decision Tree Guidance." fda.gov
- RAPS. "Regulatory Pathway Analysis: 510(k) vs De Novo Comparative Study." 2025. raps.org
Need a Custom Analysis?
Our proprietary risk framework includes regulatory pathway analysis and De Novo vs 510(k) strategy assessment. Get a complimentary regulatory strategy evaluation for your device.